Get the Stockscreener App
35.21
1.09%
0.38
Pre-market:
37.11
1.90
+5.40%
Edgewise Therapeutics Inc stock is traded at $35.21, with a volume of 926.73K.
It is up +1.09% in the last 24 hours and up +6.41% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
See More
Previous Close:
$34.83
Open:
$35.44
24h Volume:
926.73K
Relative Volume:
0.80
Market Cap:
$3.79B
Revenue:
-
Net Income/Loss:
$-176.01M
P/E Ratio:
-21.20
EPS:
-1.661
Net Cash Flow:
$-148.97M
1W Performance:
+1.06%
1M Performance:
+6.41%
6M Performance:
+47.08%
1Y Performance:
+130.28%
1-Day Range:
$34.72
$36.90
1-Week Range:
$32.50
$36.90
52-Week Range:
$12.15
$40.77
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
35.21 | 3.79B | 0 | -176.01M | -148.97M | -1.661 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Goldman | Neutral |
| Jul-30-25 | Initiated | Raymond James | Strong Buy |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Apr-30-25 | Initiated | Guggenheim | Buy |
| Apr-02-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
(EWTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Number of shareholders of Edgewise Therapeutics, Inc. – NASDAQ:EWTX - TradingView
Edgewise Therapeutics, Inc. 2026 Annual Meeting Results and SEC Filing Details - Minichart
Edgewise Therapeutics Shareholders Back Board and Governance - TipRanks
Edgewise Therapeutics (EWTX) shareholders approve directors, KPMG and executive pay - Stock Titan
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement - Seeking Alpha
Paradigm Biocapital Advisors LP's Edgewise Therapeutics Inc(EWTX) Holding History - GuruFocus
Liquidity Mapping Around (EWTX) Price Events - Stock Traders Daily
Edgewise Therapeutics Reports Inducement Grants As Permitted By Nasdaq Listing Rules - TradingView
Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - 富途牛牛
Guggenheim Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX) - The Globe and Mail
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal - Medical Dialogues
New Edgewise hires get 74,000 stock options as hiring inducement - Stock Titan
Edgewise sells sevasemten for up to $2.65 billion - The Pharma Letter
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal - The Globe and Mail
Assessing Edgewise Therapeutics (EWTX) Valuation After A Sharp Recent Share Price Move - Yahoo Finance
EWTX Maintained by HC Wainwright & Co. -- Price Target Raised to $45 - GuruFocus
EWTX Maintained by Wedbush -- Price Target Raised to $52.00 - GuruFocus
RBC Capital lowers Edgewise Therapeutics stock price target on deal By Investing.com - Investing.com Australia
RBC Capital lowers Edgewise Therapeutics stock price target on deal - Investing.com
RBC Lowers Price Target on Edgewise Therapeutics to $48 From $50, Keeps Outperform, Speculative Risk - marketscreener.com
Wedbush raises Edgewise Therapeutics stock price target on Servier deal - Investing.com UK
Wedbush raises Edgewise Therapeutics stock price target on Servier deal By Investing.com - Investing.com India
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn - Yahoo Finance
Edgewise Therapeutics, IBM, Rubrik - TradingView
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics - MedCity News
Edgewise Therapeutics (EWTX) Surges 17.5% on Market Activity - GuruFocus
How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang - Investor's Business Daily
Servier to Acquire Edgewise Therapeutics (EWTX) for $2.65 Billio - GuruFocus
Raymond James raises Edgewise Therapeutics price target on Servier deal By Investing.com - Investing.com Canada
Edgewise Therapeutics stock hits all-time high of 40.6 USD By Investing.com - Investing.com South Africa
Servier Pharmaceuticals LLC and LES LABORATOIRES SERVIER, SAS entered into an Asset Purchase Agreement to acquire Sevasemten and Muscular Dystrophy Business of Edgewise Therapeutics, Inc. for $2.7 billion.. - marketscreener.com
Edgewise sells muscular dystrophy assets to Servier for $2.65B - BioWorld News
Servier buys into muscular dystrophy with potentially $2.7B deal - BioPharma Dive
Edgewise Therapeutics Shares Surge 15% to $39.40 on Promising Muscle Disease Treatment Data - International Business Times Australia
Why is Edgewise Therapeutics stock surging today? By Investing.com - Investing.com Canada
EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business - Yahoo Finance
Servier Agrees to Acquire Muscular Dystrophy Business of Edgewise Therapeutics - Contract Pharma
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn - European Biotechnology Magazine
Edgewise Therapeutics Sells Sevasemten, Refocuses on Cardiology - TipRanks
Edgewise Therapeutics stock hits all-time high of 40.6 USD - Investing.com
Edgewise Therapeutics Sells Sevasemten for Up to $2.65 Billion, Refocuses on Cardiovascular Pipeline - Minichart
Servier projette d'acquérir l'activité dystrophie musculaire d'Edgewise Therapeutics - PR Newswire
Edgewise sells muscular dystrophy unit to Servier for $2.65B By Investing.com - Investing.com Australia
Servier to acquire Edgewise muscular dystrophy unit for $2.65b By Investing.com - Investing.com South Africa
France: Servier acquires muscular dystrophy business of Edgewise Therapeutics for up to US$2.65bn - Investors in Healthcare
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business - The Manila Times
Edgewise sells muscular dystrophy unit to Servier for $2.65B - Investing.com
Edgewise Therapeutics (EWTX) to sell sevasemten business to Servier for up to $2.65B - Stock Titan
Edgewise's Muscular Dystrophy Business to be Acquired by Servier for Up to $2.65 Billion - marketscreener.com
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Edgewise Therapeutics Inc Stock (EWTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Donovan Joanne M. | CMO |
May 05 '26 |
Option Exercise |
7.08 |
50,000 |
354,000 |
54,367 |
| Donovan Joanne M. | CMO |
May 05 '26 |
Sale |
38.57 |
50,000 |
1,928,400 |
4,367 |
| Donovan Joanne M. | CMO |
May 04 '26 |
Sale |
31.29 |
5,230 |
163,663 |
4,367 |
| Donovan Joanne M. | CMO |
Apr 01 '26 |
Option Exercise |
7.08 |
28,662 |
202,927 |
38,259 |
| Donovan Joanne M. | CMO |
Apr 01 '26 |
Sale |
32.31 |
28,662 |
926,095 |
9,597 |
| Donovan Joanne M. | CMO |
Mar 31 '26 |
Option Exercise |
7.08 |
21,338 |
151,073 |
30,935 |
| Donovan Joanne M. | CMO |
Mar 31 '26 |
Sale |
32.12 |
21,338 |
685,308 |
9,597 |
| Donovan Joanne M. | CMO |
Mar 27 '26 |
Sale |
30.98 |
16,358 |
506,735 |
9,597 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):